ALIGATER Trademark

Research and development in the field of biotechnology and targeted gene therapy, namely, research and development based on a platform for the discovery, identification and manufacture of viral systems and vectors chemically conjugated with various types of functional ligands, namely, DNA viruses such as adeno-associated viruses (AAVs); Biological research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Biomedical research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Pharmaceutical research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Research and development in the field of pharmaceuticals relating to conjugated viral systems and viral vectors

Pharmaceutical preparations in the form of viral systems, gene therapy systems, viral vectors and gene therapy vectors, namely, chemically conjugated viral systems and viral vectors, DNA viruses such as adeno-associated viruses (AAVs) for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Pharmaceutical preparations containing viral vectors for gene therapy; Medicinal preparations for medical, pharmaceutical or veterinary use comprising conjugated viral systems and viral vectors for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Chemical reagents for medical purposes; Chemical reagents for veterinary purposes; Biological reagents for medical purposes; Biological reagents for veterinary purposes; Pharmaceutical preparations for cellular therapy for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Therapeutic biological preparations for use in targeted medical and clinical gene therapy, namely, for ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders, comprising conjugated viral systems and viral vectors; Biological preparations for use in cell cultures for medical purposes